View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
December 13, 2018updated 12 Jul 2022 1:09pm

Rafael launches Phase III trial of pancreatic cancer drug

Rafael Pharmaceuticals has commenced the Phase III AVENGER 500 trial to examine CPI-613 (devimistat) in combination with modified folfirinox (mFFX) as first-line therapy to treat patients with metastatic adenocarcinoma of pancreas.

Rafael Pharmaceuticals has commenced the Phase III AVENGER 500 trial to examine CPI-613 (devimistat) in combination with modified folfirinox (mFFX) as first-line therapy to treat patients with metastatic adenocarcinoma of pancreas.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The multicentre, open-label, randomised pivotal trial will compare the efficacy and safety of folfirinox (FFX) with the combination of CPI-613 and mFFX.

It is expected to enrol around 500 metastatic (stage IV) pancreatic adenocarcinoma patients aged between 18 and 75 years who were not previously treated for metastatic disease.

Individuals with Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 will also be included in the AVENGER 500 trial.

Primary endpoints of the trial are overall response rate (ORR) and progression-free survival (PFS).

Its secondary endpoints include overall survival (OS) and duration of response (DOR).

“The current data on CPI-613 in combination with modified folfirinox in patients battling pancreatic cancer is immensely promising.”

Rafael expects to complete the interim analysis of the trial by the second quarter of 2020.

AVENGER 500 trial principal investigator Philip A Philip said: “Pancreatic cancer is the deadliest cancer worldwide with very limited treatment options.

“The current data on CPI-613 in combination with modified folfirinox in patients battling pancreatic cancer is immensely promising.”

CPI-613 is based on the Altered Metabolism Directed (AMD) platform and is designed to target altered regulation of metabolic processes specific to cancer cells.

The drug was used in a previous Phase I, single-centre, open-label, dose-escalation study called CCCWFU 57112.

The trial was designed to analyse the safety, tolerability and efficacy of CPI-613 in combination with mFFX as frontline therapy in patients with metastatic pancreatic cancer.

It included a total of 18 patients who received 500mg/m² dose of the study drug combination.

Findings from the trial showed that the treatment was well tolerated among patients with no deaths reported due to adverse events.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena